Your request to link to rcsb for PIK3CG/PIK3R1

• 1E7U: structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, ly294002, quercetin, myricetin and staurosporine (10.1016/S1097-2765(05)00089-4 )
• 1E7V: structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, ly294002, quercetin, myricetin and staurosporine (10.1016/S1097-2765(05)00089-4 )
• 1E8W: structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, ly294002, quercetin, myricetin and staurosporine (10.1016/S1097-2765(05)00089-4 )
• 1E8X: structural insights into phoshoinositide 3-kinase enzymatic mechanism and signalling (10.1016/S1097-2765(05)00089-4 )
• 1E8Y: structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, ly294002, quercetin, myricetin and staurosporine (10.1016/S1097-2765(05)00089-4 )
• 1E8Z: structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, ly294002, quercetin, myricetin and staurosporine (10.1016/S1097-2765(05)00089-4 )
• 1E90: structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, ly294002, quercetin, myricetin and staurosporine (10.1016/S1097-2765(05)00089-4 )
• 1HE8: ras g12v - pi 3-kinase gamma complex (10.1016/S0092-8674(00)00196-3 )
• 2A4Z: crystal structure of human pi3kgamma complexed with as604850 (10.1038/NM1284 )
• 2A5U: crystal structure of human pi3kgamma complexed with as605240 (10.1038/NM1284 )
• 2CHW: a pharmacological map of the pi3-k family defines a role for p110 alpha in signaling: the structure of complex of phosphoinositide 3- kinase gamma with inhibitor pik-39 (10.1016/J.CELL.2006.03.035 )
• 2CHX: a pharmacological map of the pi3-k family defines a role for p110alpha in signaling: the structure of complex of phosphoinositide 3-kinase gamma with inhibitor pik-90 (10.1016/J.CELL.2006.03.035 )
• 2CHZ: a pharmacological map of the pi3-k family defines a role for p110alpha in signaling: the structure of complex of phosphoinositide 3-kinase gamma with inhibitor pik-93 (10.1016/J.CELL.2006.03.035 )
• 2V4L: complex of human phosphoinositide 3-kinase catalytic subunit gamma (p110 gamma) with pik-284 (10.1038/NCHEMBIO.117 )
• 3APC: crystal structure of human pi3k-gamma in complex with ch5132799 (10.1016/J.BMCL.2011.01.065 )
• 3APD: crystal structure of human pi3k-gamma in complex with ch5108134 (10.1016/J.BMCL.2011.01.065 )
• 3APF: crystal structure of human pi3k-gamma in complex with ch5039699 (10.1016/J.BMCL.2011.01.065 )
• 3CSF: crystal structure of pi3k p110gamma catalytical domain in complex with organoruthenium inhibitor dw2 (10.1021/CB800039Y )
• 3CST: crystal structure of pi3k p110gamma catalytical domain in complex with organoruthenium inhibitor e5e2 (10.1021/CB800039Y )
• 3DBS: structure of pi3k gamma in complex with gdc0941 (10.1021/JM800295D )
• 3DPD: achieving multi-isoform pi3k inhibition in a series of substituted 3,4-dihydro-2h-benzo[1,4]oxazines (10.1016/J.BMCL.2008.06.104 )
• 3ENE: complex of pi3k gamma with an inhibitor (10.1038/NCHEMBIO.117 )
• 3IBE: crystal structure of a pyrazolopyrimidine inhibitor bound to pi3 kinase gamma (10.1021/JM900851F )
• 3L08: structure of pi3k gamma with a potent inhibitor: gsk2126458 (10.1021/ML900028R )
• 3L13: crystal structures of pan-pi3-kinase and dual pan-pi3-kinase/mtor inhibitors (10.1021/JM901284W )
• 3L16: discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-pi3-kinase and dual pan-pi3- kinase/mtor inhibitors for the treatment of cancer (10.1021/JM901284W )
• 3L17: discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-pi3-kinase and dual pan-pi3- kinase/mtor inhibitors for the treatment of cancer (10.1021/JM901284W )
• 3L54: structure of pi3k gamma with inhibitor (10.1021/ML900028R )
• 3LJ3: pi3-kinase-gamma with a pyrrolopyridine-benzofuran inhibitor (10.1016/J.BMCL.2010.01.135 )
• 3MJW: pi3 kinase gamma with a benzofuranone inhibitor (10.1016/J.BMCL.2010.04.139 )
• 3ML8: discovery of the highly potent pi3k/mtor dual inhibitor pf-04691502 through structure based drug design (10.1021/ML300309H )
• 3ML9: discovery of the highly potent pi3k/mtor dual inhibitor pf-04691502 through structure based drug design (10.1021/ML300309H )
• 3NZS: structure-based optimization of pyrazolo -pyrimidine and -pyridine inhibitors of pi3-kinase (10.1016/J.BMCL.2010.08.067 )
• 3NZU: structure-based optimization of pyrazolo -pyrimidine and -pyridine inhibitors of pi3-kinase (10.1016/J.BMCL.2010.08.067 )
• 3OAW: 4-methylpteridineones as orally active and selective pi3k/mtor dual inhibitors (10.1016/J.BMCL.2010.08.045 )
• 3P2B: crystal structure of pi3k gamma with 3-(2-morpholino-6-(pyridin-3- ylamino)pyrimidin-4-yl)phenol (10.1016/J.BMCL.2010.10.021 )
• 3PRE: quinazolines with intra-molecular hydrogen bonding scaffold (imhbs) as pi3k/mtor dual inhibitors. (10.1016/J.BMCL.2010.12.026 )
• 3PRZ: quinazolines with intra-molecular hydrogen bonding scaffold (imhbs) as pi3k/mtor dual inhibitors. (10.1016/J.BMCL.2010.12.026 )
• 3PS6: quinazolines with intra-molecular hydrogen bonding scaffold (imhbs) as pi3k/mtor dual inhibitors. (10.1016/J.BMCL.2010.12.026 )
• 3QAQ: crystal structure of pi3k-gamma in complex with triazine-benzimidazole 1 (10.1016/J.BMCL.2011.02.007 )
• 3QAR: crystal structure of pi3k-gamma in complex with triazine-benzimidazole 32 (10.1016/J.BMCL.2011.02.007 )
• 3QJZ: crystal structure of pi3k-gamma in complex with benzothiazole 1 (10.1021/JM1014605 )
• 3QK0: crystal structure of pi3k-gamma in complex with benzothiazole 82 (10.1021/JM1014605 )
• 3R7Q: structure-based design of thienobenzoxepin inhibitors of pi3- kinase (10.1016/J.BMCL.2011.04.124 )
• 3R7R: structure-based design of thienobenzoxepin inhibitors of pi3-kinase (10.1016/J.BMCL.2011.04.124 )
• 3S2A: crystal structure of pi3k-gamma in complex with a quinoline inhibitor (10.1021/JM200386S )
• 3SD5: crystal structure of pi3k gamma with 5-(2,4-dimorpholinopyrimidin-6- yl)-4-(trifluoromethyl)pyridin-2-amine (10.1158/1535-7163.MCT-11-0474 )
• 3T8M: rational design of pi3k-alpha inhibitors that exhibit selectivity over the pi3k-beta isoform
• 3TJP: crystal structure of pi3k gamma with n6-(3,4-dimethoxyphenyl)-2- morpholino-[4,5'-bipyrimidine]-2',6-diamine
• 3TL5: discovery of gdc-0980: a potent, selective, and orally available class i phosphatidylinositol 3-kinase (pi3k)/mammalian target of rapamycin (mtor) kinase inhibitor for the treatment of cancer (10.1021/JM2009327 )
• 3ZVV: fragment bound to pi3kinase gamma (10.1016/J.BMCL.2011.07.117 )
• 3ZW3: fragment based discovery of a novel and selective pi3 kinase inhibitor (10.1016/J.BMCL.2011.07.117 )
• 4ANU: complexes of pi3kgamma with isoform selective inhibitors. (10.1021/JM300403A )
• 4ANV: complexes of pi3kgamma with isoform selective inhibitors. (10.1021/JM300403A )
• 4ANW: complexes of pi3kgamma with isoform selective inhibitors. (10.1021/JM300403A )
• 4ANX: complexes of pi3kgamma with isoform selective inhibitors. (10.1021/JM300403A )
• 4AOF: selective small molecule inhibitor discovered by chemoproteomic assay platform reveals regulation of th17 cell differentiation by pi3kgamma (10.1038/NCHEMBIO.957 )
• 4DK5: crystal structure of human pi3k-gamma in complex with a pyridyl- triazine inhibitor (10.1021/JM300184S )
• 4EZJ: potent and selective inhibitors of pi3k-delta: obtaining isoform selectivity from the affinity pocket and tryptophan shelf (10.1016/J.BMCL.2012.05.027 )
• 4EZK: potent and selective inhibitors of pi3k-delta: obtaining isoform selectivity from the affinity pocket and tryptophan shelf (10.1016/J.BMCL.2012.05.027 )
• 4EZL: potent and selective inhibitors of pi3k-delta: obtaining isoform selectivity from the affinity pocket and tryptophan shelf (10.1016/J.BMCL.2012.05.027 )
• 4F1S: crystal structure of human pi3k-gamma in complex with a pyridyl- triazine-sulfonamide inhibitor (10.1016/J.BMCL.2012.06.078 )
• 4FA6: design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of pi3ka and mtor (10.1016/J.BMCL.2012.05.100 )
• 4FAD: design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of pi3ka and mtor (10.1016/J.BMCL.2012.05.100 )
• 4FHJ: crystal structure of pi3k-gamma in complex with imidazopyridine 2 (10.1016/J.BMCL.2012.06.033 )
• 4FHK: crystal structure of pi3k-gamma in complex with imidazopyridazine 19e (10.1016/J.BMCL.2012.06.033 )
• 4FJY: crystal structure of pi3k-gamma in complex with quinoline-indoline inhibitor 24f (10.1021/JM300679U )
• 4FJZ: crystal structure of pi3k-gamma in complex with pyrrolo-pyridine inhibitor 63 (10.1021/JM300679U )
• 4FLH: crystal structure of human pi3k-gamma in complex with amg511 (10.1021/JM300846Z )
• 4FUL: pi3 kinase gamma bound to a pyrmidine inhibitor (10.1016/J.BMCL.2012.08.107 )
• 4G11: x-ray structure of pi3k-gamma bound to a 4-(morpholin-4-yl)- (6-oxo-1, 6-dihydropyrimidin-2-yl)amide inhibitor (10.1016/J.BMCL.2012.08.072 )
• 4GB9: potent and highly selective benzimidazole inhibitors of pi3k-delta (10.1021/JM300717C )
• 4HLE: compound 21 (1-alkyl-substituted 1,2,4-triazoles) (10.1016/J.BMCL.2012.10.121 )
• 4HVB: catalytic unit of pi3kg in complex with pi3k/mtor dual inhibitor pf- 04979064 (10.1021/ML300309H )
• 4J6I: discovery of thiazolobenzoxepin pi3-kinase inhibitors that spare the pi3-kinase beta isoform (10.1016/J.BMCL.2013.02.102 )
• 4KZ0: structure of pi3k gamma with imidazopyridine inhibitors (10.1016/J.BMCL.2013.06.010 )
• 4KZC: structure of pi3k gamma with imidazopyridine inhibitors (10.1016/J.BMCL.2013.06.010 )
• 4PS3: structure of pi3k gamma in complex with 1-[6-(5-methoxypyridin-3-yl)- 1,3-benzothiazol-2-yl]-3-[2-(1-propyl-1h-imidazol-4-yl)ethyl]urea (10.1021/JM500362J )
• 4PS7: structure of pi3k gamma in complex with n-[6-(pyridin-3-yl)-1,3- benzothiazol-2-yl]acetamide (10.1021/JM500362J )
• 4PS8: structure of pi3k gamma in complex with n-[6-(5,6-dimethoxypyridin-3- yl)-1,3-benzothiazol-2-yl]acetamide (10.1021/JM500362J )
• 4URK: pi3kg in complex with azd6482 (10.1016/J.BMCL.2014.07.007 )
• 4WWN: crystal structure of human pi3k-gamma in complex with (s)-n-(1-(7- fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9h-purin-6-amine amg319 inhibitor (10.1021/JM501624R )
• 4WWO: crystal structure of human pi3k-gamma in complex with phenylquinoline inhibitor n-{(1s)-1-[8-chloro-2-(3-fluorophenyl)quinolin-3-yl]ethyl}- 9h-purin-6-amine (10.1021/JM501624R )
• 4WWP: crystal structure of human pi3k-gamma in complex with pyridinylquinoline inhibitor n-{(1s)-1-[8-chloro-2-(2-methylpyridin- 3-yl)quinolin-3-yl]ethyl}-9h-purin-6-amine (10.1021/JM501624R )
• 4XX5: structure of pi3k gamma in complex with an inhibitor
• 4XZ4: structure of pi3k gamma in complex with an inhibitor
• 5EDS: crystal structure of human pi3k-gamma in complex with benzimidazole inhibitor 5 (10.1021/ACS.JMEDCHEM.5B01651 )
• 5G2N: x-ray structure of pi3kinase gamma in complex with copanlisib (10.1002/CMDC.201600148 )
• 5G55: 3-quinoline carboxamides inhibitors of pi3k (10.1021/ACS.JMEDCHEM.6B00519 )
• 5JHA: structure of phosphoinositide 3-kinase gamma (pi3k) bound to the potent inhibitor pikin2 (10.1038/NCOMMS14683 )
• 5JHB: structure of phosphoinositide 3-kinase gamma (pi3k) bound to the potent inhibitor pikin3 (10.1038/NCOMMS14683 )
• 5KAE: crystal structure of human pi3k-gamma in complex with quinoline- containing inhibitor 5g
• 5OQ4: pqr309 - a potent, brain-penetrant, orally bioavailable, pan-class i pi3k/mtor inhibitor as clinical candidate in oncology (10.1021/ACS.JMEDCHEM.7B00930 )
• 5T23: pi3kg in complex with 5d (10.1016/J.BMCL.2016.11.004 )
• 6AUD: pi3k-gamma k802t in complex with cpd 8 10-((1-(tert-butyl)piperidin-4- yl)sulfinyl)-2-(1-isopropyl-1h-1,2,4-triazol-5-yl)-5,6- dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine (10.1021/ACSMEDCHEMLETT.7B00170 )
• 6C1S: phosphoinositide 3-kinase gamma bound to an pyrrolopyridinone inhibitor (10.1021/ACS.JMEDCHEM.8B00085 )
• 6FH5: pi3kg in complex with compound 7
• 6GQ7: pi3kg in complex with inh
• 6T3B: crystal structure of pi3kgamma with a dihydropurinone inhibitor (compound 4) (10.1021/ACS.JMEDCHEM.9B01684 )
• 6T3C: crystal structure of pi3kgamma in complex with dna-pk inhibitor azd7648 (10.1021/ACS.JMEDCHEM.9B01684 )
• 6XRL: crystal structure of human pi3k-gamma in complex with inhibitor ipi- 549 (10.1021/ACS.JMEDCHEM.0C01203 )
• 6XRM: crystal structure of human pi3k-gamma in complex with compound 4 (10.1021/ACS.JMEDCHEM.0C01203 )